Specific apoCIII proteoform ratios are associated with a healthier cardiometabolic phenotype and lower incidence of type 2 diabetes: a nested case-control study

Abstract Background Apolipoprotein CIII (apoCIII) is a key regulator of triglyceride metabolism and an emerging biomarker of cardiometabolic risk. Although elevated total apoCIII concentrations have been associated with type 2 diabetes (T2D) and cardiovascular disease, individual apoCIII proteoforms may exert distinct metabolic effects. We investigated the prospective associations between apoCIII proteoforms and incident T2D in adults at high cardiometabolic risk, as well as their associations with dietary intake. Methods This nested case-control study included 594 incident T2D cases and 594 controls matched for age, sex, intervention group, body mass index, fasting glucose and triglyceride concentrations. Seven apoCIII proteoforms were measured using mass spectrometry-based immunoassay, and total apoCIII concentrations were measured using an immunoturbidimetric assay. Associations between apoCIII proteoforms and metabolic traits, dietary factors, and incident T2D were evaluated using multivariable-adjusted regression models. Results ApoCIII proteoforms showed heterogeneous associations with metabolic risk and incident T2D. Higher CIII2d/CIII1, CIII2/CIII1, and CIII0f/CIII1 ratios were associated with more favourable lipid and glycaemic profiles and lower odds of incident T2D per 1-SD increase (CIII2d/CIII1 OR = 0.77, 95% CI: 0.61–0.97; CIII2/CIII1 OR = 0.81, 95% CI: 0.69–0.96; CIII0f/CIII1 OR = 0.73, 95% CI: 0.55–0.97). Exploratory analyses identified several nominal associations between dietary intake and apoCIII proteoform ratios; however, none remained statistically significant after FDR correction. Conclusions Higher CIII2d/CIII1, CIII2/CIII1, and CIII0f/CIII1 proteoform ratios were associated with healthier lipid and glucose metabolic profiles and lower odds of incident T2D. These findings support further investigation of apoCIII proteoform profiling as a potential biomarker of incident T2D risk.

Authors

Institutions

Publication Details

Journal
Cardiovascular Diabetology
Published
2026-11-13
DOI
https://doi.org/10.1186/s12933-026-03445-0
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Specific apoCIII proteoform ratios are associated with a healthier cardiometabolic phenotype and lower incidence of type 2 diabetes: a nested case-control study

Josep Antoni Tur, Lidia Daimiel, Carolina Ortega‐Azorín, José David Torres-Peña et al.
2 links
Cardiovascular Diabetology
Diabetes, Cardiovascular Risks, and Lipoproteins
article

Specific apoCIII proteoform ratios are associated with a healthier cardiometabolic phenotype and lower incidence of type 2 diabetes: a nested case-control study

Josep Antoni Tur, Lidia Daimiel, Carolina Ortega‐Azorín, José David Torres-Peña, Jordi Salas‐Salvadó, Josép Vidal, Antonio García‐Ríos, Dolores Corella, Miguel Ruiz‐Canela, Xavier Pintó, José López‐Miranda, Albert Goday, Rosa Mª Casas, Lucas Tojal‐Sierra, Helmut Schröder, Ángel M. Alonso‐Gómez, Jesús Vioqué, Clotilde Vázquez, Josefa Girona, Jesús Francisco García-Gavilán, Víctor José Simón‐Frapolli, Estefanía Toledo, Laura Torres‐Collado, Julia Wärnberǵ, Miguel Ángel Martínez‐González, Diego Martínez‐Urbistondo, Aurora Bueno‐Cavanillas, Dora Romaguera, Nuria Goñi, Miguel Delgado‐Rodríguez, Napoleón Pérez‐Farinós, Emilio Ros, Montse Guardiola, Lluís Serra‐Majem, Olga Castañer, Josep Ribalta, Victor Urbano-Fernández, José Alfredo Martínez, Pilar Matía-Martín, Fitó Montserrat, Eva M. Asensio, Ramón Estruch, Concepció Barceló, Helena Banús, Francisco José Tinahones, Vicente Martín Sánchez, Miquel Fiol, M. Angeles Castillo-Hermoso, Pere Rehues
article en

Abstract

Abstract Background Apolipoprotein CIII (apoCIII) is a key regulator of triglyceride metabolism and an emerging biomarker of cardiometabolic risk. Although elevated total apoCIII concentrations have been associated with type 2 diabetes (T2D) and cardiovascular disease, individual apoCIII proteoforms may exert distinct metabolic effects. We investigated the prospective associations between apoCIII proteoforms and incident T2D in adults at high cardiometabolic risk, as well as their associations with dietary intake. Methods This nested case-control study included 594 incident T2D cases and 594 controls matched for age, sex, intervention group, body mass index, fasting glucose and triglyceride concentrations. Seven apoCIII proteoforms were measured using mass spectrometry-based immunoassay, and total apoCIII concentrations were measured using an immunoturbidimetric assay. Associations between apoCIII proteoforms and metabolic traits, dietary factors, and incident T2D were evaluated using multivariable-adjusted regression models. Results ApoCIII proteoforms showed heterogeneous associations with metabolic risk and incident T2D. Higher CIII2d/CIII1, CIII2/CIII1, and CIII0f/CIII1 ratios were associated with more favourable lipid and glycaemic profiles and lower odds of incident T2D per 1-SD increase (CIII2d/CIII1 OR = 0.77, 95% CI: 0.61–0.97; CIII2/CIII1 OR = 0.81, 95% CI: 0.69–0.96; CIII0f/CIII1 OR = 0.73, 95% CI: 0.55–0.97). Exploratory analyses identified several nominal associations between dietary intake and apoCIII proteoform ratios; however, none remained statistically significant after FDR correction. Conclusions Higher CIII2d/CIII1, CIII2/CIII1, and CIII0f/CIII1 proteoform ratios were associated with healthier lipid and glucose metabolic profiles and lower odds of incident T2D. These findings support further investigation of apoCIII proteoform profiling as a potential biomarker of incident T2D risk.

Cardiovascular Diabetology
Madrid Institute for Advanced Studies (ES), Universitat de Miguel Hernández d'Elx (ES), Universidad San Pablo CEU (ES), Universidad de Las Palmas de Gran Canaria (ES), Karolinska University Hospital (SE), Harvard University (US), Universitat de València (ES), University of the Basque Country (ES), Universitat Pompeu Fabra (ES), Universidad de Granada (ES), Universidad de Jaén (ES), Instituto de Salud Carlos III (ES), Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (ES), Bellvitge University Hospital (ES), Karolinska Institutet (SE), Hospital Clínico San Carlos (ES), Servicio Navarro de Salud (ES), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES), Instituto Maimónides de Investigación Biomédica de Córdoba (ES), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), Institut de Recerca Biomèdica Catalunya Sud (ES), Hospital Universitario Araba (ES), Navarre Institute of Health Research (ES), Centro de Investigación Biomédica en Red (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario Reina Sofía (ES), Osakidetza (ES), Health Research Institute of the Balearic Islands (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Del Mar (ES), Clinica Universidad de Navarra (ES), Municipal Institute for Medical Research (ES), Comunidad de Madrid (ES), IMDEA Food (ES), Andalusian Centre for Nanomedicine and Biotechnology (ES), Hospital Universitario Son Espases (ES), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Hospital del Mar Research Institute (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Instituto de Investigación Biomédica de Málaga (ES), Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES), Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES), Universitat de les Illes Balears (ES), University of Córdoba (ES), Universitat Rovira i Virgili (ES), Universidad Autónoma de Madrid (ES), Universitat de Barcelona (ES), Universidad de Sevilla (ES), Universidad de Málaga (ES), Universidad de Navarra (ES), Universidad de León (ES)
European Research Council, Instituto de Salud Carlos III
Good health and well-being
Diabetes, Cardiovascular Risks, and Lipoproteins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon